UroGen Pharma stock
URGNNASDAQUroGen Pharma Ltd., HealthcareISIN IL0011407140
36Score 36 out of 100, Weak
Price and trend
40 / 100
Price history
+5.0% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 17% below it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 26).
The price is 48% below its 52-week high. Largest decline in 10 years: 94% (May 2018 to May 2025).
Chart figures for advanced users
- SMA 50$37.38
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$31.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)26
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$17.00
- The lowest closing price of the last twelve months.
- Resistance$50.29
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- UroGen Pharma Ltd. belongs to the Biotechnology industry (United States) and, with a market value of $1.29B, is number 167 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $109.79M (up 21.4% year on year) and a loss of $153.49M.
- For fiscal 2026, analysts expect on average revenue of $319.42M (up 190.9%) and adjusted earnings per share of −$0.27.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 600 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 56.2% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- DilutionShare count up 121% since 2020.Capital allocation 18
- Loss-makingLoss of $65.75M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$132.05M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 159% on the twelve months before. Revenue turned from negative at the start of the period to positive ($109.79M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 89%, operating −114%, net −140%. Last 12 months: net −26%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 4 Nov 2026EPS reported −$0.03 (expected $0.11)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 20.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.27−20.7%
- Revenue
- $319.42M−0.9%
- Earnings per share
- $2.71+7.7%
- Revenue
- $531.05M−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.2%2026 revenue guidance of $97 to $101 million stands, with only operating expense guidance raised to $260 to $270 million.
“We continue to expect JELMYTO net product revenue of $97 million to $101 million for 2026, which represents growth of roughly 3% to 7% over 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $3.93M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Degnan ChrisSale
8 Oct 2026, Chief Financial Officer
- Shares
- 2,202
- Price
- $36.69
- Value
- $80,791
- Schoenberg MarkSale
8 Sept 2026, Chief Medical Officer
- Shares
- 871
- Price
- $42.92
- Value
- $37,383
- Smith Jason DrewSale
8 Sept 2026, General Counsel
- Shares
- 1,519
- Price
- $42.54
- Value
- $64,618
Show 4 more
- Schoenberg MarkSale
20 Aug 2026, Chief Medical Officer
- Shares
- 60,677
- Price
- $47.05
- Value
- $2.85M
- Schoenberg MarkSale
9 Jul 2026, Chief Medical Officer
- Shares
- 10,000
- Price
- $40.00
- Value
- $400,000
- Schoenberg MarkSale
22 Jun 2026, Chief Medical Officer
- Shares
- 10,000
- Price
- $35.01
- Value
- $350,100
- Schoenberg MarkSale
8 Jun 2026, Chief Medical Officer
- Shares
- 5,222
- Price
- $27.30
- Value
- $142,561
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at UroGen Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- InnovivaINVA $1.35B67
- MannKindMNKD $1.34B39
- Pharma MarPHM.MC $1.31B59
- OmerosOMER $1.3B52
- Inhibrx BiosciencesINBX $1.29B33
- COMPASS PathwaysCMPS $1.28B35
- IdorsiaIDIA.SW $1.28B35
- Nektar TherapeuticsNKTR $1.27B29
ETFs that hold UroGen Pharma
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.12% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.10% | 0.40% | €813.42M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.08% | 0.35% | €1.25B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.